… Short-acting beta2-agonists (SABA) were the most frequent respiratory medications prescribed
in the 12 months before the index date among COPD patients aged ≥ 40 years in CPRD …

… Approximately 72% of individuals filled some reliever medication, most commonly short-acting
beta2-agonists (SABAs) as metered dose inhaler and SABA/SAMA nebulized solutions. …

… Long-acting beta2-agonists (LABAs) should not be taken for 12 hours prior to spirometry.The
National Asthma Council recommends different withholding times (see Table 2).…

… short-acting beta2-agonists (SABA) or long-acting beta2-agonists (LABA), including inhalation
solutions); R03B (Other drugs for obstructive airway diseases, inhalants, such as inhaled …

… Acute bronchitis is an acute respiratory infection with a normal chest radiograph that is …
Beta2 agonists have shown statistically significant enhancement of mucociliary clearance rates in …

… Our results show that in a model of viral infection, administering the combination therapy
while increasing cAMP levels can further decrease inflammatory cytokines prompting further …

… Inhaled beta2-agonists can induce cardiac side effects in patients with HF, such as
ischaemia, tachycardia, arrhythmias, hypokalaemia, QT prolongation, disturbed autonomic …

… 29.42%; p= 0.043) diagnoses were lower for TIO+ OLO with 24% reduced risk of experiencing
pneumonia/acute bronchitis/bronchiolitis diagnosis (adjusted HR= 0.76; 95% CI: 0.60-0.97…

… Pharmacological prevention of exacerbations has been demonstrated in asthma using
monoclonal anti-IgE with long-acting inhaled beta2 agonists in addition to inhaled corticosteroid …

… In asthma therapy long-acting beta2-agonists (LABA) enhance the function of corticosteroids
and improve asthma control [10]. A possible explanation of this efficacy is represented by a …